In a nutshell
This study examined whether use of beta-blockers could slow the progression of non small-cell lung cancer.
Some background
Treatment of non small-cell lung cancer (NSCLC) is often limited due to the rapid progression of the cancer and high recurrence rates. The mechanisms responsible for the rapid spread of NSCLC are unclear, but the hormone norepinephrine is known to cause cancer cells to migrate. Norepinephrine acts by binding to a specific structure on the surface of the cells, the beta-adrenergic receptor. These receptors can be blocked by a class of drugs known as beta-blockers. Beta blockers are common drugs used for the treatment of heart diseases.
Methods & findings
The study examined the records of 722 patients diagnosed with NSCLC and treated with radiotherapy. 157 of these patients were also receiving beta blockers for the treatment of an unrelated condition. Patients also receiving beta blockers experienced a 33% decreased risk for distant metastasis and a 26% decrease in the risk of early recurrence or death.
The bottom line
This study concluded that beta blockers may delay cancer progression in NSCLC patients.
The fine print
This analysis was performed in a retrospective manner from the records of patients participating in several different studies. Further controlled studies should be performed to reach definitive conclusions.
What’s next?
Consult with your physician regarding the risks and benefits of beta-blockers, and their potential use in delaying progression or recurrence of NCSLC.
Published By :
Annals of oncology
Date :
May 01, 2013
